Topas Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Topas Therapeutics's estimated annual revenue is currently $4.2M per year.
- Topas Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Topas Therapeutics has 27 Employees.
- Topas Therapeutics grew their employee count by 13% last year.
Topas Therapeutics's People
| Name | Title | Email/Phone |
|---|
Topas Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Topas Therapeutics?
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver's natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas' investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
keywords:N/A
N/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Topas Therapeutics News
... and participated in several financing rounds and successful spin-offs, such as Topas Therapeutics, Celmatix and CureXsys.
Other Companies in Hamburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3M | 27 | 42% | N/A |
#2 | $2.7M | 27 | 35% | N/A |
#3 | $1.9M | 27 | N/A | N/A |
#4 | $2.5M | 28 | N/A | N/A |
#5 | $4.9M | 28 | -12% | N/A |